Loading...
Market
Who will acquire Grifols by the end of 2025?
2
Resolution / Starting Odds
Brookfield Asset Management • 25%
Private Equity Firm • 25%
Pharmaceutical Company • 25%
No Acquisition • 25%
Official announcements from Grifols SA or potential acquiring companies
Story
Brookfield Abandons Grifols Acquisition, Stock Plummets
Nov 27, 2024, 09:01 AM
Brookfield Asset Management is reportedly preparing to abandon its plans to acquire Spanish drug-maker Grifols SA due to disagreements over valuation. Grifols' board recently rejected Brookfield's indicative offer, leading to a significant drop in Grifols' stock price. The shares fell as much as 17% after the news broke, with the company's stock plummeting by 12% on the day. The potential withdrawal of the offer has also impacted the broader market, with the IBEX 35 index losing 11,600 points. The Grifols family has indicated they won't support a new bid by a third-party to take the company private.
View original story
Similar markets
Biotech Company • 25%
Pharmaceutical Company • 25%
Medical Device Company • 25%
No major acquisition • 25%
Approved without conditions • 25%
Approved with conditions • 25%
Rejected • 25%
No reattempt made • 25%
Johnson & Johnson • 25%
Pfizer • 25%
GlaxoSmithKline • 25%
Other • 25%
Increase Bitcoin holdings • 25%
Invest in another cryptocurrency • 25%
Invest in traditional assets • 25%
No major investment move • 25%
Pfizer • 25%
AstraZeneca • 25%
GlaxoSmithKline • 25%
Other • 25%
Pfizer • 25%
Roche • 25%
Novo Nordisk • 25%
Other • 25%
Biotech company • 25%
Pharmaceutical company • 25%
Medical device company • 25%
Other • 25%
Wave Life Sciences • 25%
CRISPR Therapeutics • 25%
Moderna • 25%
Other • 25%
A cancer diagnostics company • 25%
A gene sequencing company • 25%
A biotech company unrelated to cancer diagnostics • 25%
No major acquisition • 25%